Russell Investments Group Ltd. Has $192,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Russell Investments Group Ltd. reduced its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 71.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,212 shares of the company's stock after selling 18,162 shares during the quarter. Russell Investments Group Ltd.'s holdings in Castle Biosciences were worth $192,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in shares of Castle Biosciences during the 4th quarter valued at about $19,244,000. Vanguard Group Inc. boosted its holdings in Castle Biosciences by 4.8% during the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock valued at $48,837,000 after purchasing an additional 83,783 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of Castle Biosciences in the 4th quarter valued at approximately $1,959,000. Trexquant Investment LP raised its holdings in shares of Castle Biosciences by 27.5% in the 4th quarter. Trexquant Investment LP now owns 203,571 shares of the company's stock worth $5,425,000 after buying an additional 43,947 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Castle Biosciences by 165.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock worth $1,980,000 after buying an additional 43,241 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Transactions at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 2,130 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the sale, the insider now directly owns 78,335 shares of the company's stock, valued at $1,529,099.20. This represents a 2.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,321 shares of company stock worth $774,644. Company insiders own 7.20% of the company's stock.

Castle Biosciences Trading Down 1.4 %

Castle Biosciences stock opened at $20.63 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The stock has a 50-day simple moving average of $21.04 and a 200 day simple moving average of $26.58. The stock has a market capitalization of $595.07 million, a P/E ratio of 103.16 and a beta of 1.11. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84.

Analysts Set New Price Targets

Several brokerages recently issued reports on CSTL. Robert W. Baird lifted their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $38.75.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.